Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Jul 5:374:n1682.
doi: 10.1136/bmj.n1682.

Aducanumab for Alzheimer's disease?

Sebastian Walsh  1 , Richard Merrick  2 , Richard Milne  3 , Carol Brayne  2
Affiliations
Editorial

Aducanumab for Alzheimer's disease?

Sebastian Walsh et al. BMJ. .

Abstract

Patients and families need hope, not false hope

PubMed Disclaimer

Conflict of interest statement

Competing interests: The BMJ has judged that there are no disqualifying financial ties to commercial companies. The authors declare no other interests. Provenance and peer review: Commissioned; not externally peer reviewed.

References

    1. Mahase E. Three FDA advisory panel members resign over approval of Alzheimer’s drug. BMJ 2021;373:n1503. 10.1136/bmj.n1503. - DOI - PubMed
    1. Walsh S, King E, Brayne C. France removes state funding for dementia drugs. 2019. - PubMed
    1. Sevigny J, Chiao P, Bussière T, et al. . The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature 2016;537:50-6. 10.1038/nature19323. - DOI - PubMed
    1. US Food & Drug Administration. Combined FDA and applicant PCNS drugs advisory committee briefing document. 2020. https://www.fda.gov/media/143502/download
    1. Ackley SF, Zimmerman SC, Brenowitz WD, et al. . Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis. BMJ 2021;372:n156. 10.1136/bmj.n156. - DOI - PMC - PubMed

Publication types

Substances